Kanako Shimizu - Search Results

Year	Number of Results
2002	1
2003	5
2004	2
2006	2
2007	4
2008	1
2009	5
2010	7
2011	4
2012	1
2013	7
2014	2
2015	2
2016	5
2017	5
2018	3
2019	5
2020	5
2021	1
2022	6
2023	5
2024	2

1

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.

Iyoda T, Yamasaki S, Ueda S, Shimizu K, Fujii SI. Iyoda T, et al. Among authors: shimizu k. Biomolecules. 2023 Feb 10;13(2):348. doi: 10.3390/biom13020348. Biomolecules. 2023. PMID: 36830717 Free PMC article. Review.

2

Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.

Okada M, Shimizu K, Fujii SI. Okada M, et al. Among authors: shimizu k. Int J Mol Sci. 2022 Feb 26;23(5):2594. doi: 10.3390/ijms23052594. Int J Mol Sci. 2022. PMID: 35269735 Free PMC article. Review.

3

Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer.

Fujii SI, Shimizu K. Fujii SI, et al. Among authors: shimizu k. Trends Immunol. 2019 Nov;40(11):984-997. doi: 10.1016/j.it.2019.09.008. Epub 2019 Oct 31. Trends Immunol. 2019. PMID: 31676264 Review.

4

Immune suppression and reversal of the suppressive tumor microenvironment.

Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii SI. Shimizu K, et al. Int Immunol. 2018 Sep 25;30(10):445-454. doi: 10.1093/intimm/dxy042. Int Immunol. 2018. PMID: 29939325 Review.

5

Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.

Okada M, Shimizu K, Nakazato H, Yamasaki S, Fujii SI. Okada M, et al. Among authors: shimizu k. Mol Ther Methods Clin Dev. 2023 May 16;29:541-555. doi: 10.1016/j.omtm.2023.05.014. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37359417 Free PMC article.

6

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies.

Shimizu K, Iyoda T, Yamasaki S, Kadowaki N, Tojo A, Fujii AS. Shimizu K, et al. Cancers (Basel). 2020 Mar 28;12(4):817. doi: 10.3390/cancers12040817. Cancers (Basel). 2020. PMID: 32231116 Free PMC article. Review.

7

PD-L1 Expression Affects Neoantigen Presentation.

Okada M, Shimizu K, Iyoda T, Ueda S, Shinga J, Mochizuki Y, Watanabe T, Ohara O, Fujii SI. Okada M, et al. Among authors: shimizu k. iScience. 2020 Jun 26;23(6):101238. doi: 10.1016/j.isci.2020.101238. Epub 2020 Jun 4. iScience. 2020. PMID: 32629606 Free PMC article.

8

Adjuvant activity mediated by iNKT cells.

Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M. Fujii S, et al. Among authors: shimizu k. Semin Immunol. 2010 Apr;22(2):97-102. doi: 10.1016/j.smim.2009.10.002. Epub 2009 Nov 24. Semin Immunol. 2010. PMID: 19939703 Review.

9

NKT cells as an ideal anti-tumor immunotherapeutic.

Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. Fujii S, et al. Among authors: shimizu k. Front Immunol. 2013 Dec 2;4:409. doi: 10.3389/fimmu.2013.00409. Front Immunol. 2013. PMID: 24348476 Free PMC article. Review.

10

Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8⁺ T cells against tumor.

Shimizu K, Ueda S, Kawamura M, Aoshima H, Satoh M, Nakabayashi J, Fujii SI. Shimizu K, et al. J Immunother Cancer. 2023 Jul;11(7):e006409. doi: 10.1136/jitc-2022-006409. J Immunother Cancer. 2023. PMID: 37400134 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year